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Study).	 Plasma	 MBL	 levels	 were	 measured	 using	 enzyme‐linked	 immunosorbent	
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1  | INTRODUC TION
Venous	thromboembolism	(VTE),	including	DVT	and	pulmonary	em‐
bolism,	affects	1	to	2	per	1000	 individuals	each	year.	 It	 is	a	major	
public	health	challenge	because	of	short‐term	and	 long‐term	com‐
plications,	 such	 as	 frequent	 recurrence	 and	 potentially	 death.1‒4 
Inherited	and	environmental	risk	factors	along	with	changes	in	blood	
flow,	hypercoagulability,	or	dysfunction	of	the	vessel	wall	affect	in‐



















may	suggest	 that	complement	C3	 is	a	mediator	 rather	 than	only	a	
marker	of	VTE	risk.




with	 serine	 proteases	 called	 MBL‐associated	 serine	 protease‐1,	
MBL‐associated	serine	protease‐2,	and	MBL‐associated	serine	pro‐
tease‐3	(MASPs‐1,‐2,‐3).14,15	The	MASP‐1	and	MASP‐2	are	activated	
when	MBL	binds	 to	 specific	 carbohydrate	 structures	 on	microbial	
and	cell	surfaces.	This	leads	to	cleavage	of	complement	factors	C4	
and	C2	 and	 the	 formation	 of	C4b2b	 convertase,	with	 subsequent	
activation	 of	C3	 and	 the	 common	 complement	 pathway.16 In vitro 
studies	have	shown	that	MASP‐1	has	thrombinlike	activity	and	can	
cleave	 factor	XIII	 (FXIII),	 fibrinogen,	 high‐molecular‐weight	 kinino‐
gen,	 and	 thrombin‐activatable	 fibrinolysis	 inhibitor,	while	MASP‐2	
can	 cleave	prothrombin	 to	 thrombin.15,17	The	MASPs	 can	 activate	




spite	 a	 moderate	 increase	 during	 an	 acute‐phase	 response.21,22 
The	MBL	levels	vary	markedly	between	individuals	because	of	the	







protect	 against	 development	 of	 VTE.	 However,	 in	 patients	 with	
systemic	 lupus	 erythematosus,	MBL2‐deficient	 genotypes	 were	
associated	with	increased28	or	unchanged29	risk	of	VTE,	whereas	
low	 plasma	 levels	 of	 MBL	 (<100	 ng/mL)	 were	 associated	 with	
increased	 VTE	 risk	 in	 a	 small	 case‐control	 study	 recruited	 from	
the	 general	 population.30	 The	 conflicting	 results	 may	 partly	 be	
explained	 by	 chance	 because	 of	 the	 low	number	 of	 participants	
included	 in	 these	 studies,	 inconsistent	 patient	 selections,	 or	 the	
retrospective	 nature	 of	 the	 case‐control	 study	 with	 the	 poten‐




Conclusions: Our	 findings	suggest	 that	 low	plasma	MBL	 levels	are	associated	with	
reduced	risk	of	VTE,	and	DVT	in	particular.










•	 The	 OR	 for	 VTE	 decreased	 with	 decreasing	 time	 be‐
tween	blood	sampling	and	event.






The	 Tromsø	 Study	 is	 a	 single‐center,	 population‐based	 cohort,	

















jective	 confirmation	 by	 radiological	 procedures,	 which	 resulted	 in	
initiation	of	 treatment	 (unless	 contraindications	were	 specified).	A	
VTE	occurring	in	the	presence	of	one	or	more	provoking	factors	was	
classified	 as	 provoked.	 Provoking	 factors	 were	 surgery	 or	 trauma	
(within	8	weeks	before	 the	 event),	 acute	medical	 condition	 (acute	

















Body	 mass	 index	 (BMI)	 was	 calculated	 as	 weight	 divided	 by	 the	
square	 of	 height	 in	meters	 (kg/m2).	 A	 self‐administered	 question‐
naire	was	used	to	collect	a	detailed	history	of	previous	cardiovascular	
disease	(CVD)	events	(stroke,	angina	pectoris,	transient	ischemic	at‐
tack,	 and	myocardial	 infarction),	 recurrent	 VTE,	 diabetes	mellitus,	
and	 other	 concurrent	 diseases.	 The	 questionnaire	 also	 included	
questions	about	dietary	habits,	physical	exercise,	 smoking,	and	al‐
cohol	consumption.
2.3 | Blood sample collection and storage of 
blood products
At	 inclusion	 in	 Tromsø	 4	 (1994‐1995),	 non‐fasting	 blood	 was	 col‐
lected	 from	 an	 antecubital	 vein	 into	 5‐mL	 vacutainers	 (Becton	








at 13 000 g	to	obtain	platelet‐freeplasma.









intraindividual	 and	 interindividual	 coefficients	 of	 variation	 were	














culated the P	 value	 for	 linear	 trend	 across	 decreasing	quartiles	 of	
MBL.	Separate	analyses	were	also	conducted	with	unprovoked	VTE,	
DVT,	and	PE	as	the	outcomes.
The	 results	 were	 based	 on	 a	 single	 baseline	 measurement	
with	 long	 follow‐up	 (>12	years	 for	many	 individuals)	 and	 could	be	
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Q2 (435‐1367  
ng/mL)




n 310 320 311 325
Age	(years) 62	±	13 60	±	13 61	±	14 59	±	15
Sex,	%	men	(n) 44.5	(138) 45.6	(146) 43.7	(136) 54.7	(178)
BMI,	kg/m2 26.8	±	4.3 26.7	±	4.4 26.7	±	4.3 25.4	±	3.8
Smoking,	%	(n) 28.7	(89) 28.4	(91) 28.3	(88) 38.8	(126)
hsCRP,	mg/L 1.71	±	1.5 1.67	±	1.4 1.50	±	1.2 1.63	±	1.4
CVDa,	%	(n) 16.1	(50) 13.1	(42) 18.0	(56) 16.3	(53)
Cancerb,	%	(n) 3.1	(10) 6.8	(21) 4.4	(14) 3.9	(12)






TA B L E  1  Distribution	of	baseline	
characteristics	according	to	quartiles	of	
plasma	levels	of	MBL























in	 participants	 without	 cancer	 (Table	 S1)	 and	 without	 those	 who	
developed	myocardial	 infarction	 or	 stroke	 or	 had	 acute	 infections	






































genotype	was	not	associated	with	 risk	of	VTE.29	 In	a	 cross‐sectional	
Quartiles of MBL (ng/mL) Controls Cases
Model 1 Model 2
OR (95% CI) OR (95% CI)
Overall	VTE
≥2423 212 113 Reference Reference
1368‐2422 213 98 0.87	(0.62‐1.21) 0.81	(0.58‐1.13)
435‐1367 212 108 0.96	(0.69‐1.33) 0.88	(0.63‐1.22)
<435 212 98 0.87	(0.62‐1.21) 0.79	(0.56‐1.10)
P	for	trend 0.6 0.2
DVT
≥2423 212 75 Reference Reference
1368‐2422 213 63 0.84	(0.57‐1.23) 0.79	(0.53‐1.17)
435‐1367 212 65 0.87	(0.59‐1.27) 0.80	(0.54‐1.18)
<435 212 57 0.76	(0.51‐1.13) 0.70	(0.47‐1.04)
P	for	trend 0.2 0.1
PE
≥2423 212 38 Reference Reference
1368‐2422 213 35 0.92	(0.56‐1.52) 0.85	(0.51‐1.41)
435‐1367 212 43 1.14	(0.71‐1.84) 1.04	(0.64‐1.69)





















complications.	 Systemic	 lupus	 erythematosus40	 and	 acute	 infectious	
diseases41	are	associated	with	increased	risk	of	VTE	and	may	therefore	





















pathway	 to	 thrombogenesis.15,17‒19,44	 Both	 MASP‐1	 and	 MASP‐2	





a	 receptor	 responsible	 for	 the	 activation	 and	 aggregation	of	 plate‐
lets	as	well	as	proinflammatory	processes	such	as	leukocyte	recruit‐











thrombus	formation	both	 in vitro and in vivo	 in	a	mouse	thrombosis	
Quartiles of MBL 
(ng/mL) Controls Cases
Model 1 Model 2
OR (95% CI) OR (95% CI)
Unprovoked	VTE
≥2423 212 46 Reference Reference
1368‐2422 213 42 0.93	(0.59‐1.47) 0.85	(0.53‐1.36)
435‐1367 212 47 1.04	(0.66‐1.63) 0.94	(0.60‐1.49)
<435 212 41 0.92	(0.58‐1.46) 0.80	(0.50‐1.29)
P	for	trend 0.9 0.5
Unprovoked	DVT
≥2423 212 28 Ref Ref
1368‐2422 213 29 1.05	(0.60‐1.84) 0.98	(0.55‐1.72)
435‐1367 212 26 0.95	(0.53‐1.67) 0.86	(0.48‐1.53)
<435 212 21 0.78	(0.43‐1.42) 0.67	(0.36‐1.24)
P	for	trend 0.4 0.2
Unprovoked	PE
≥2423 212 18 Ref Ref
1368‐2422 213 13 0.74	(0.35‐1.54) 0.68	(0.32‐1.43)
435‐1367 212 21 1.19	(0.62‐2.30) 1.09	(0.56‐2.12)























be	associated	with	VTE	risk40,41,56,57 and could thereby counterbal‐
ance	the	potential	beneficial	effect	of	MBL	deficiency.	Mannose‐
binding	 lectin	 deficiency	 has	 been	 associated	 with	 advanced	
atherosclerosis58,59	 and	a	higher	 risk	of	myocardial	 infarction,	 in‐








matched	controls	 from	the	same	source	population.	 It	 is	a	 large	
prospective	 study	 where	 blood	 samples	 were	 collected	 before	
VTE,	 allowing	 assumptions	 on	 the	 direction	 of	 the	 association	
between	 exposure	 (plasma	 levels	 of	 MBL)	 and	 outcome	 (VTE).	
The	 blood	 samples	 used	 for	 plasma	 MBL	 analysis	 were	 drawn	
in	1994‐1995	and	stored	at	−80°C	 for	up	 to	22	years.	The	 long	
storage	 time	 could	 potentially	 affect	 the	 plasma	 levels	 of	MBL.	
However,	 it	 is	 unlikely	 that	 it	 would	 affect	 the	 results,	 as	 the	
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F I G U R E  1  Plots	of	estimated	ORs	for	overall	VTE,	DVT,	and	PE	as	a	function	of	time	from	blood	sampling	in	the	fourth	survey	of	the	
Tromsø	Study	(1994‐1995)	and	event	in	analyses	adjusted	for	age,	sex,	BMI,	and	hsCRP.	Large,	solid	circles	indicate	ORs	with	P	values	<	0.05.	
CI,	confidence	interval;	DVT,	deep	vein	thrombosis;	OR,	odds	ratio;	PE,	pulmonary	embolism;	VTE,	venous	thromboembolism
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